Carolina Business Review: Panel Interview with BioAgilytix CEO Jim Datin

BioAgilytix in the News

35 years of NC Biotech
5 November, 2019

Triangle-based BioAgilytix Acquires Cambridge CRO, Plans Hiring, More Acquisitions

North Carolina Biotechnology Center covers BioAgilytix’s recent acquisition of Cambridge Biomedical in the world’s major biotech center, as well as its plans for future hiring and acquisitions.

Read More

WRALtechwire
4 November, 2019

Durham-based BioAgilytix acquires Massachusetts biomedical firm

The WRAL TechWire covers BioAgilytix’s recent acquisition of Massachusetts-based Cambridge Biomedical, and how it plans to unite two science-led teams to expand its footprint in this area of biotech innovation.

Read More

TBJ logo
14 October, 2019

TBJ reveals the 2019 Fast 50 Awards winners

The Triangle Business Journal is unveiling the 2019 Fast 50 Award winners (BioAgilytix featured).

Read More

Bioanalysis Zone logo
25 September, 2019

Webinar Q&A follow up – exploratory biomarker testing: to qualify or validate the assay?

Afshin Safavi, PhD (Founder and Board Member, BioAgilytix, NC, USA) share his responses to the questions posed by our audience during the live webinar event, “Exploratory biomarker testing: to qualify…

Read More

DE TIJD logo
6 November, 2018

Cobepa plant vlag in Amerikaanse farma

De Belgische investeringsmaatschappij Cobepa koopt BioAgilytix, een Amerikaans bedrijf dat testen uitvoert voor de farma- en biotechsector. Het is de tweede deal van Cobepa in de VS.

Read More

Private Equity News logo
6 November, 2018

Riverside Partners to Score 7.4-Times Return on BioAgilytix

Riverside Partners is set to earn a lofty return from its sale of BioAgilytix Labs LLC, a Durham, N.C.-based provider of molecular bioanalysis services. The Boston firm is expected to earn a 7.4-times money-on-money return and an internal rate of return of about 50% on the sale, according to a person familiar with the matter. The sale is expected to return half of the invested capital from Riverside’s $561 million fifth fund, or about $280 million, the person said.

Read More

TBJ logo
5 November, 2018

BioAgilytix CEO talks strategy after buyout: ‘You’ll be seeing us make acquisitions’

Bioagilytix, a 2018 Triangle Business Journal Fast 50 Awards winner, will have even more wind blowing into its sails as the company is about to be acquired by a Belgium firm.

Read More

WRAL TechWire logo
5 November, 2018

Belgian investment company acquires Durham biotesting firm BioAgilytix

Durham-based BioAgilytix, a fast-growing provider of bioanalytical testing services for large-molecule drugs, will be acquired by a privately held Belgian investment company. The acquisition will provide BioAgilytix with increased capital and resources to meet growing demand for its services, said Jim Datin, president and chief executive officer, who also serves on the North Carolina Biotechnology Center’s board of directors.

Read More

TBJ logo
2 November, 2018

Durham’s BioAgilytix to be acquired by European investment firm

BioAgilytix is on the verge of being acquired by an international firm that is expected to bring a lot more money into the expanding company’s portfolio. The Durham-based company announced that Cobepa S.A. a private, Brussels-based investment company will close a deal acquiring the company later this month. Financial details of the deal have not been disclosed.

Read More

BioSpace logo
22 August, 2018

15 Fastest-Growing Private Life Science Companies in the U.S.

Inc. magazine collates an annual list of the fastest-growing private companies in America. This year, 15 of the top 5,000 were related to healthcare, medical devices and biopharma. Many of them were clinical research organizations (CROs) or consultancies that help biopharma companies move through the development, regulatory and commercial processes.

Read More